Market News / Story
Cerenome (CNSY) Launches CSF DNA/RNA Molecular Profiling Tests
·
Cerenome launched CNSide CSF Molecular Profile tests in the U.S., expanding its CSF diagnostics beyond leptomeningeal metastases to primary CNS tumors, CNS metastases, and hematologic CNS disease, with ordering available from Oct. 12, 2026. Material Details #DetailAI Analyst View1Launch of CSF DNA/RNA profiling testsNew products can expand addressable market and revenue optionality.2Ordering starts Oct 12, 2026 (U.S.)Near-term commercial availability sets timing for…